Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise | Psychedelic Invest

VANCOUVER, British Columbia, June 03, 2024–(BUSINESS WIRE)–Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a biopharmaceutical company focused on developing transformative medicines

June 3, 2024

CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy that costs $3.5M

With its $3.5 million price tag, CSL Behring and uniQure’s one-off hemophilia B gene therapy Hemgenix is one of the world’s most expensive therapies. On

February 10, 2024

Opinion | What If the Doctor Is Out?

Rosenbaum is a pediatrician and pediatrics professor. Brophy is an organizational sociologist and professor of health policy & management. Chief Complaint: Los Angeles House Staff

September 24, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.